Multiple Sclerosis and Related Disorders

Understanding of the peripheral immune system in MS 2:53
Understanding of the peripheral immune system in MS
João José Cerqueira • 27 Apr 2023
Occurrence of PIRA in RRMS: current understanding 2:02
Occurrence of PIRA in RRMS: current understanding
João José Cerqueira • 27 Apr 2023
Results of ocrelizumab in treatment-naïve patients with early relapsing MS 5:20
Results of ocrelizumab in treatment-naïve patients with early relapsing MS
João José Cerqueira • 27 Apr 2023
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD 2:51
Association of B-cell subsets and AQP4 antibody titers with disease activity in NMOSD
Friedemann Paul • 27 Apr 2023
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study 1:56
Inebilizumab in AQP4+ NMOSD patients with history of immunosuppression treatment: N-MOmentum study
Friedemann Paul • 27 Apr 2023
AAN highlights: NMOSD and MOGAD 1:06
AAN highlights: NMOSD and MOGAD
Friedemann Paul • 27 Apr 2023
Proposed criteria for the diagnosis of MOGAD 1:46
Proposed criteria for the diagnosis of MOGAD
Friedemann Paul • 27 Apr 2023
sGFAP as a biomarker in NMOSD 3:14
sGFAP as a biomarker in NMOSD
Friedemann Paul • 27 Apr 2023
MS therapies: limited direct effect in CNS pathology 2:29
MS therapies: limited direct effect in CNS pathology
Augusto A. Miravalle • 5 May 2023
The potential of BTKIs in multiple sclerosis 3:31
The potential of BTKIs in multiple sclerosis
Giancarlo Comi • 27 Mar 2023
Deciphering MS silent progression 2:46
Deciphering MS silent progression
Celia Oreja-Guevara • 24 Mar 2023
Inclusion of optical nerve lesions the McDonald diagnostic criteria 4:18
Inclusion of optical nerve lesions the McDonald diagnostic criteria
Giancarlo Comi • 27 Mar 2023
Effects of menopause in women with MS: Cervantes scale 2:39
Effects of menopause in women with MS: Cervantes scale
Celia Oreja-Guevara • 24 Mar 2023
Controversies in MS: prodrome, DMTs & biomarkers 1:11
Controversies in MS: prodrome, DMTs & biomarkers
Celia Oreja-Guevara • 24 Mar 2023
Digital technology to characterize and monitor MS 3:32
Digital technology to characterize and monitor MS
László Vécsei • 10 Mar 2023
Progressive MS: emerging treatments 1:42
Progressive MS: emerging treatments
Emily Evans • 21 Feb 2023
The content of VJNeurology is intended for healthcare professionals